An open label, multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects with Advanced Solid Tumours or with B-cell Malignancies and in Combination with Temozolomide(TMZ) or with Carboplatin and Paclitaxel in Subjects with Advanced Solid Tumors.

Trial Profile

An open label, multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects with Advanced Solid Tumours or with B-cell Malignancies and in Combination with Temozolomide(TMZ) or with Carboplatin and Paclitaxel in Subjects with Advanced Solid Tumors.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 05 Apr 2017

At a glance

  • Drugs 2X 121 (Primary) ; Carboplatin; Paclitaxel; Temozolomide
  • Indications B cell lymphoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Eisai Co Ltd
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 05 Apr 2017 Results (n=28) assessing PK and PD in adult patients with refractory solid tumours and B-cell lymphoma, presented at the 108th Annual Meeting of the American Association for Cancer Research
    • 28 Mar 2017 Single agent data will be presented at the American Association for Cancer Research (AACR) 2017 Annual Meeting, according to an Eisai Inc. media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top